% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lena:275459,
author = {A. Lena and U. Wilkenshoff and S. Hadzibegovic and J.
Porthun and L. Rösnick and A.-K. Fröhlich and T. Zeller
and M. Karakas and U. Keller$^*$ and J. Ahn and L.
Bullinger$^*$ and H. Riess and S. D. Rosen and A. R. Lyon
and T. F. Lüscher and M. Totzeck and T. Rassaf and D.
Burkhoff and M. R. Mehra and J. J. Bax and J. Butler and F.
Edelmann and W. Haverkamp and S. D. Anker and M. Packer and
A. J. S. Coats and S. von Haehling and U. Landmesser and M.
S. Anker},
title = {{C}linical and {P}rognostic {R}elevance of {C}ardiac
{W}asting in {P}atients {W}ith {A}dvanced {C}ancer},
journal = {Journal of the American College of Cardiology},
volume = {81},
number = {16},
issn = {0735-1097},
address = {New York, NY},
publisher = {American College of Cardiology},
reportid = {DKFZ-2023-00774},
pages = {1569 - 1586},
year = {2023},
abstract = {Background:Body wasting in patients with cancer can affect
the heart.Objectives:The frequency, extent, and clinical and
prognostic importance of cardiac wasting in cancer patients
is unknown.Methods:This study prospectively enrolled 300
patients with mostly advanced, active cancer but without
significant cardiovascular disease or infection. These
patients were compared with 60 healthy control subjects and
60 patients with chronic heart failure (ejection fraction
$<40\%)$ of similar age and sex distribution.Results:Cancer
patients presented with lower left ventricular (LV) mass
than healthy control subjects or heart failure patients
(assessed by transthoracic echocardiography: 177 ± 47 g vs
203 ± 64 g vs 300 ± 71 g, respectively; P < 0.001). LV
mass was lowest in cancer patients with cachexia (153 ± 42
g; P < 0.001). Importantly, the presence of low LV mass was
independent of previous cardiotoxic anticancer therapy. In
90 cancer patients with a second echocardiogram after 122 ±
71 days, LV mass had declined by $9.3\%$ ± $1.4\%$ (P <
0.001). In cancer patients with cardiac wasting during
follow-up, stroke volume decreased (P < 0.001) and resting
heart rate increased over time (P = 0.001). During follow-up
of on average 16 months, 149 patients died (1-year all-cause
mortality $43\%;$ $95\%$ CI: $37\%-49\%).$ LV mass and LV
mass adjusted for height squared were independent prognostic
markers (both P < 0.05). Adjustment of LV mass for body
surface area masked the observed survival impact. LV mass
below the prognostically relevant cutpoints in cancer was
associated with reduced overall functional status and lower
physical performance.Conclusions:Low LV mass is associated
with poor functional status and increased all-cause
mortality in cancer. These findings provide clinical
evidence of cardiac wasting–associated cardiomyopathy in
cancer.},
cin = {BE01},
ddc = {610},
cid = {I:(DE-He78)BE01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37076211},
doi = {10.1016/j.jacc.2023.02.039},
url = {https://inrepo02.dkfz.de/record/275459},
}